norepinephrine

Norepinephrine identity evidence

Record what supports norepinephrine identification and what alternatives the evidence excludes.

1. Which structure-linked reference establishes that this referent is norepinephrine rather than epinephrine, dopamine or another catecholamine? definition
2. Which analytical observations distinguish norepinephrine from the related compounds present in this material? measurement

Stereochemical reference

Separate verified configuration from naming conventions and unresolved composition.

1. Is absolute configuration or enantiomeric composition established, and by what evidence? measurement
2. Does the source use norepinephrine, noradrenaline or an abbreviation for the same specified substance, or leave its identity ambiguous? boundary

Presentation resolution

Identify the chemical presentation needed to interpret composition and transformations.

1. Is the material specified as norepinephrine free base, a named salt with known hydration, or norepinephrine in a stated solution? definition
2. Which label, certificate or analysis establishes counterion, stoichiometry and water basis? provenance

Active-moiety equivalence

Record the denominator, chemical basis and evidence supporting any quantity conversion.

1. Does the reported value count norepinephrine active moiety, total salt mass, concentration in a matrix or amount collected over time? measurement
2. Are composition, units and volume or collection interval sufficiently known to convert the value without assuming missing information? action

Sampled norepinephrine

Record the biological matrix or prepared medium and contextual factors required for comparison.

1. Which matrix or compartment was sampled, at what time, and with what timed-collection basis if applicable? provenance
2. Which collection, preservation, posture, activity and medication conditions does the applicable norepinephrine assay require the agent to retain? measurement

Assay-specific confidence

Preserve calibration, interference, recovery and quantification evidence for norepinephrine.

1. What calibration and quality-control evidence supports this norepinephrine result in this matrix? measurement
2. Were related catecholamines, metabolites and other method-specific interferences resolved, and is the result within the validated quantification range? measurement

Retained norepinephrine

Assess degradation using applicable evidence rather than a universal shelf-life assumption.

1. What temperature, light, oxygen, pH and elapsed-time history is known for this norepinephrine material? provenance
2. Which applicable stability data, appearance criteria and potency or impurity measurements support its present integrity? measurement

Supported preparation action

Specify whether a proposed manipulation is supported for this concentration, medium and container.

1. Which product-specific or validated laboratory evidence supports the proposed diluent, concentration, container and contact duration? action
2. What missing compatibility or integrity evidence requires withholding the proposed preparation step? boundary

Contextualized occurrence

Separate observed presence, inferred origin and evidence of biological activity.

1. What evidence supports endogenous, administered, laboratory-added or mixed origin for this norepinephrine occurrence? provenance
2. Which compartment, exposure timing and receptor or response observations support a claim of activity, and what remains unmeasured? boundary

Norepinephrine use boundary

Keep reagent identity, medicinal-product suitability and patient-specific decisions distinct.

1. Does the evidence establish suitability as an analytical standard, research reagent or component of the specified medicinal preparation? action
2. Which linked product and clinical protocol records must govern route, administration, monitoring and response to adverse exposure? boundary

Kinds and varieties

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Peripheral sympathetic neurotransmitter released from postganglionic noradrenergic terminals
• Central noradrenergic neurotransmitter of locus coeruleus and related brainstem nuclei
• Circulating hormone secreted by adrenal-medullary chromaffin cells
• Intravenous vasopressor drug (norepinephrine/noradrenaline infusion, e.g. Levophed)
• (R)-L-norepinephrine, the endogenous and pharmaceutical enantiomer, versus racemic or (S) material
• Pharmaceutical salts: bitartrate/tartrate injection versus hydrochloride
• Clinical laboratory analyte (plasma or urine free norepinephrine in a fractionated catecholamine panel)

1. Which of these kinds and varieties hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Identifiers and schemes

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Wikidata - Q186242 - Wikidata item for norepinephrine.
• CAS Registry Number - 51-41-2 - L-(R)-norepinephrine free base; racemate is 138-65-8; l-tartrate (1:1) is 51-40-1.
• PubChem CID - 439260 - Compound record for (R)-norepinephrine.
• INN (WHO) - norepinephrine - International Nonproprietary Name; Latin norepinephrinum, Spanish norepinefrina.
• BAN - noradrenaline - British Approved Name, still used in UK/Commonwealth product names.
• DrugBank - DB00368 - Drug record for the pharmaceutical substance.
• RxNorm RXCUI - 7512 - NLM RxNorm concept for norepinephrine.
• ATC - C01CA03 - WHO ATC code: cardiac stimulants excl. cardiac glycosides, adrenergic and dopaminergic agents.
• HMDB - HMDB0000216 - Human Metabolome Database entry.
• EPA DSSTox - DTXSID5023378 - CompTox substance identifier.
• IUPAC name - 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol - Preferred IUPAC name of the endogenous enantiomer; formula C8H11NO3.

1. Which of these identifiers and schemes hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Standards and regulation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• U.S. FDA - LEVOPHED (norepinephrine bitartrate) injection, initial approval 1950, indicated to restore blood pressure in adult acute hypotensive states; labeling requires dilution in dextrose-containing solutions and warns against saline as the sole diluent.
• WHO INN Programme - recommended international nonproprietary name norepinephrine (distinct from the BAN noradrenaline).
• MHRA / UK SmPC - licensed noradrenaline (norepinephrine) tartrate concentrate for emergency restoration of blood pressure in acute hypotension; specifies tartrate-to-base equivalence and controlled-rate infusion.
• Surviving Sepsis Campaign (SCCM / ESICM) - norepinephrine as first-line vasopressor for septic shock that remains hypotensive after fluid resuscitation.
• UN GHS - ACS records GHS hazard classification for the neat chemical (laboratory handling), separate from the sterile injectable monograph.

1. Which of these standards and regulation hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Real-world use

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• First-line continuous intravenous vasopressor in ICU septic shock after fluids, titrated to a mean arterial pressure target (commonly ≥65 mmHg).
• Short-term restoration of blood pressure in other acute hypotensive states, including some cardiogenic, neurogenic and anaesthetic hypotensions.
• Hospital product as 1 mg/mL base concentrate (2 mg/mL tartrate), typically diluted to about 40 mg/L base and given by syringe or infusion pump, preferably via a central venous catheter.
• Endogenous mediator of sympathetic vasoconstriction, alertness and the acute stress (fight-or-flight) response.
• Plasma or urine fractionated catecholamine assay (LC-MS/MS) when excess sympathetic secretion is suspected; plasma free metanephrines are preferred for pheochromocytoma.
• Pharmacologic target of SNRIs, selective norepinephrine reuptake inhibitors and MAO inhibitors used in depression, anxiety and some pain syndromes - those drugs are not norepinephrine itself.

1. Which of these real-world use hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Typical measurements

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• molar mass - 169.18 - g/mol
• plasma norepinephrine, adult seated 15 min - 1050-4800 - pmol/L
• plasma norepinephrine, adult supine 30 min - 680-3100 - pmol/L
• plasma elimination half-life - about 2.4 - min
• adult IV infusion, initial non-weight-based rate - 8-12 to start, then titrated (usual reported ranges on the order of 2-40) - µg/min as base
• adult IV infusion, weight-based maintenance - 0.05-0.5 typical; titration steps 0.05-0.1; high-dose/refractory use may exceed 1 - µg/kg/min as base
• prepared infusion concentration (UK SmPC usual dilution) - 40 as base (80 as tartrate) - mg/L
• apparent volume of distribution / plasma protein binding - 8.8 L; about 25% bound - L ; %
• melting point (free base, decomposes) / water solubility - 217 (dec.); 0.85 - °C ; g/L
• injectable solution pH - 3.0-4.5 - pH

1. Which of these typical measurements hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Failure modes and hazards

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Extravasation of the infusion causes intense local vasoconstriction and tissue ischaemia or necrosis; phentolamine is the usual local antidote where available.
• Excess α-adrenergic constriction can worsen coronary, mesenteric or peripheral ischaemia and extend thrombosis; product information warns in patients with existing vascular thrombosis.
• β1 stimulation can provoke tachyarrhythmia or atrial fibrillation; baroreflex from the pressure rise may instead produce reflex bradycardia.
• Catechol oxidation: potency is lost on air/light exposure and, per FDA labeling, if saline is used as the sole diluent rather than a dextrose-containing solution.
• Overdose produces severe hypertension; the labeled response is to stop the infusion until the patient restabilises.
• Peripheral (non-CNS) administration does not treat central noradrenergic deficiency because norepinephrine does not cross the blood-brain barrier.
• Some formulations contain metabisulfite, a hypersensitivity hazard distinct from the catecholamine itself.
• High-dose 'refractory' shock: further dose escalation may fail to restore perfusion and is a cue to add another vasopressor or revisit the cause rather than treat the molecule as infinitely titratable.

1. Which of these failure modes and hazards hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Regional variation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• United States and WHO INN use norepinephrine; United Kingdom and many Commonwealth labels use noradrenaline, often as the dual name 'noradrenaline (norepinephrine)'.
• Laboratory and physiology abbreviations split the same way: NE in much US literature, NA in much European literature.
• Brand and synonym geography: Levophed is the widely recognised US trade name; Arterenol appears in German use; other local names include Adrenor.
• Diluent practice is not uniform: FDA labeling rejects saline as the sole diluent, while some European product information and bedside practice still prepare infusions in 0.9% sodium chloride as well as glucose 5%.
• Chinese clinical short names include 去甲肾上腺素 (and colloquial 去甲肾); Spanish INN is norepinefrina, Italian noradrenalina.

1. Which of these regional variation hold for the sense of norepinephrine this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• epinephrine (adrenaline) - Epinephrine is the N-methyl analogue with substantial β2 activity (bronchodilation, some vasodilation) and is first-line for anaphylaxis; norepinephrine lacks meaningful β2 action and is used for vasoconstrictor support of blood pressure. Fractionated catecholamine assay or the presence/absence of the N-methyl group on the structure separates them.
• dopamine - Dopamine is the biosynthetic precursor (dopamine β-hydroxylase adds the β-OH). Clinically it has dose-dependent dopaminergic then β then α effects and more tachyarrhythmia; comparative shock trials (e.g. SOAP II, as discussed in vasopressor reviews) favour norepinephrine as first-line vasopressor.
• phenylephrine - Phenylephrine is a pure α1 agonist without β1 inotropy, so blood pressure rises while cardiac output often falls and reflex bradycardia is common; norepinephrine retains some β1 support of contractility. Receptor-selectivity tables and the CO response distinguish them.
• vasopressin - Vasopressin is a V1-receptor peptide vasopressor, not a catecholamine, and is used as an adjunct rather than a substitute with the same receptor map; it is not a substrate of COMT/MAO in the catecholamine pathway.
• normetanephrine - Normetanephrine is the COMT O-methyl metabolite. Plasma free metanephrines are the preferred pheochromocytoma markers because parent norepinephrine is highly posture- and stress-sensitive; the laboratory menu (metanephrines vs fractionated catecholamines) is the practical test.
• isoproterenol - Isoproterenol is a non-selective β agonist that increases heart rate and contractility while lowering vascular resistance; norepinephrine's dominant clinical effect is α-mediated vasoconstriction with little β2 vasodilation.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of norepinephrine this model covers, and on what evidence? provenance